Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
856 questions in 87 reviews · Cystic Fibrosis and Genetic Disorders
current versionsNo studies 856 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose QoL · people with CAH Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
HC (15 mg/m²/day) vs PD (3 mg/m²/day) versus DXA (0.3 mg/m²/day) Prevention of adrenal crisis · people with CAH Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
HC (15 mg/m²/day) vs PD (3 mg/m²/day) versus DXA (0.3 mg/m²/day) Presence of osteopenia · people with CAH Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
HC (15 mg/m²/day) vs PD (3 mg/m²/day) versus DXA (0.3 mg/m²/day) Presence of testicular or ovarian adrenal rest tumours · people with CAH Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
HC (15 mg/m²/day) vs PD (3 mg/m²/day) versus DXA (0.3 mg/m²/day) Subfertility · people with CAH Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
HC (15 mg/m²/day) vs PD (3 mg/m²/day) versus DXA (0.3 mg/m²/day) Final adult height · people with CAH Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
HC (10 mg/m²/day to 15 mg/m²/day) vs PD (2.4 mg/m²/day to 3.5 mg/m²/day) QoL · people with CAH Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
HC (10 mg/m²/day to 15 mg/m²/day) vs PD (2.4 mg/m²/day to 3.5 mg/m²/day) Prevention of adrenal crisis · people with CAH Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
HC (10 mg/m²/day to 15 mg/m²/day) vs PD (2.4 mg/m²/day to 3.5 mg/m²/day) Presence of osteopenia · people with CAH Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
HC (10 mg/m²/day to 15 mg/m²/day) vs PD (2.4 mg/m²/day to 3.5 mg/m²/day) Presence of testicular or ovarian adrenal rest tumours · people with CAH Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
HC (10 mg/m²/day to 15 mg/m²/day) vs PD (2.4 mg/m²/day to 3.5 mg/m²/day) Subfertility · people with CAH Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
HC (15 mg/m²/day) vs HC (25 mg/m²/day) with fludrocortisone (0.1 mg/day) QoL · people with CAH Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
HC (15 mg/m²/day) vs HC (25 mg/m²/day) with fludrocortisone (0.1 mg/day) Prevention of adrenal crisis · people with CAH Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
HC (15 mg/m²/day) vs HC (25 mg/m²/day) with fludrocortisone (0.1 mg/day) Presence of osteopenia · people with CAH Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
HC (15 mg/m²/day) vs HC (25 mg/m²/day) with fludrocortisone (0.1 mg/day) Presence of testicular or ovarian adrenal rest tumours · people with CAH Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
HC (15 mg/m²/day) vs HC (25 mg/m²/day) with fludrocortisone (0.1 mg/day) Subfertility · people with CAH Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose Prevention of adrenal crisis · people with CAH Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose Presence of osteopenia · people with CAH Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose Presence of testicular or ovarian adrenal rest tumours · people with CAH Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose Subfertility · people with CAH Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose Final adult height · people with CAH Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
HC (15 mg/m²/day) vs PD (3 mg/m²/day) versus DXA (0.3 mg/m²/day) QoL · people with CAH Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Pain relief (percentage relief compared to baseline) · children and young adults with SCD Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Frequency of pain episodes · children and young adults with SCD Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Change in QoL · children and young adults with SCD Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Change in ability to cope with ADL · children and young adults with SCD Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention vs usual care Change in ERV (L) · postural abnormalities in people with cystic fibrosis Physical therapies for postural abnormalities in people with cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention vs usual care Change in TLC (L) · postural abnormalities in people with cystic fibrosis Physical therapies for postural abnormalities in people with cystic fibrosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo) Number of minor postoperative bleeding episodes · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… (2019) · Cochrane | This outcome was not reported in either of the trials. | 0 studies | No studies |
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo) Outcome NR · People with Von Willebrand disease undergoing minor oral surgery or dental extractions Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… (2019) · Cochrane | No randomised or quasi-randomised controlled trials in people with Von Willebrand disease met the inclusion criteria; no eligible VWD trials were identified. | 0 studies | No studies |
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo) Bleeding duration · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… (2019) · Cochrane | This outcome was not reported in either of the trials. | 0 studies | No studies |
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo) Any postoperative complication except bleeding (such as wound infection) · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… (2019) · Cochrane | This outcome was not reported in either of the trials. | 0 studies | No studies |
Intervention NR Antibiotic resistance patterns following treatment · adults and children with cystic fibrosis Once‐daily versus multiple‐daily dosing with intravenous aminoglycosides for cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ PEP vs oscillating PEP Direct measures of mucus clearance · adults and children with CF Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ PEP vs HFCWO Direct measures of mucus clearance · adults and children with CF Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ PEP vs HFCWO Exercise tolerance · adults and children with CF Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ PEP vs HFCWO Well being · adults and children with CF Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ PEP vs BiPAP Number of respiratory exacerbations · adults and children with CF Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ PEP vs BiPAP Direct measures of mucus clearance · adults and children with CF Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ PEP vs BiPAP Well being · adults and children with CF Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ PEP vs airway clearance techniques Adverse events · adults and children with cystic fibrosis Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ PEP vs PDPV LCI · adults and children with CF Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: oral vitamin E supplementation vs placebo or no treatment Nutritional status: change from baseline in BMI · children and adults with cystic fibrosis Antioxidant supplementation for lung disease in cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: oral vitamin E supplementation vs placebo or no treatment Pulmonary exacerbations: mean time to next exacerbation · children and adults with cystic fibrosis Antioxidant supplementation for lung disease in cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: oral β‐carotene vs placebo Lung function: FEV1 % predicted mean change from baseline · children and adults with cystic fibrosis Antioxidant supplementation for lung disease in cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: oral β‐carotene vs placebo Quality of life · children and adults with cystic fibrosis Antioxidant supplementation for lung disease in cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: oral β‐carotene vs placebo Nutritional status: change from baseline in BMI · children and adults with cystic fibrosis Antioxidant supplementation for lung disease in cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: oral β‐carotene vs placebo Pulmonary exacerbations: mean time to next exacerbation · children and adults with cystic fibrosis Antioxidant supplementation for lung disease in cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: oral antioxidant combination vs control Lung function: FEV1 % predicted mean change from baseline · children with cystic fibrosis Antioxidant supplementation for lung disease in cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: oral antioxidant combination vs control Lung function: FEV1 % predicted mean change from baseline · children with cystic fibrosis Antioxidant supplementation for lung disease in cystic fibrosis (2019) · Cochrane | no estimate extracted | NR | No studies |